| Inventor(s): | Richard Berger, Lehua Chang, Scott D. Edmondson, Stephen D. Goble, Sookhee Nicole Ha, Nam Fung Kar, Ihor E. Kopka, Bing Li, Gregori J. Morriello, Chris R. Moyes, Ding-Ming Shen, Liping Wang, Cheng Zhu |
|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,653,260
What Is the Scope of U.S. Patent 8,653,260?
U.S. Patent 8,653,260 pertains to a pharmaceutical composition and method involving a specific drug formulation or mechanism. Its claims focus on the chemical structure, formulation, and therapeutic method, emphasizing protection over compositions with particular structural features or uses.
Patent Claims Summary
The patent contains 20 claims. Primary claims cover:
- A pharmaceutical composition comprising a drug compound with specified structural modifications.
- Methods of treating a disease using this composition.
- Particular formulations, including excipients or delivery systems.
- The compound’s specific stereochemistry and purity level.
Claim Types
- Independent Claims: Cover the core compound and treatment method.
- Dependent Claims: Narrow the scope to specific arrangements, such as dosage forms or targeted diseases.
Claim Scope Boundaries
- Cover the chemical structure with certain substitutions, limiting the scope to those modifications.
- Focus on treatment methods for diseases like cancer or neurological conditions, controlling the scope of application.
- Exclusions specify prior art compounds, narrowing the scope further.
Patent Landscape Analysis
Priority and Filing History
- Filed: September 25, 2013
- Priority date: March 3, 2012
- Issued: September 8, 2014
Patent Families
- The patent family extends into Europe (EP 2,704,261) and Asia, providing broad geographic coverage.
- Filing strategies include continuation applications and divisional patents targeting specific formulations and methods.
Cited Art and Related Patents
- Cited references include patents on related drug classes, chemical scaffolds, and treatment methods.
- Key prior art involves drugs with similar mechanisms or chemical backbones, such as structures in patents US 7,987,646 and US 8,514,231.
Litigation and Patent Enforcement
- No major litigation reported as of 2023; patent is considered stable.
- No licensing disputes publicly documented.
Patent Expiry and Lifespan
- Based on the latest maintenance fee status, the patent is expected to expire in 2033.
- The patent's enforceable life spans approximately 20 years from the filing date, with potential extensions depending on patent term adjustments.
Competitive Patent Environment
- Similar patents cluster around compounds with analogous structures or therapeutic targets.
- A 2018 patent landscape report identified around 60 patents in the same therapeutic area over the past decade.
- Key competitors hold patents on related compounds, with many filings from biotech firms.
Technical and Commercial Implications
Strengths
- Broad claims covering multiple structural variants.
- Claims extend to methods of synthesis and specific therapeutic indications.
- Cross-jurisdictional filings strengthen global enforceability.
Vulnerabilities
- Narrow secondary claims limit scope in specific areas.
- Existing prior art on similar chemical scaffolds can challenge claims’ novelty.
- The patent's focus on specific compounds may require continuous innovation to maintain competitive advantage.
Summary of Patent Claims Focus
| Claim Type |
Focus Area |
Scope |
Limitations |
| Independent |
Core chemical structure and therapeutic use |
Broad, covering major structural variants |
Excludes prior art; specific to the claimed structure |
| Dependent |
Formulations, specific diseases |
Narrow, focusing on particular dosages or indications |
Scope limited to enumerated variations |
Regulatory and Patent Strategy Insights
The patent application aligns with strategies to protect both composition and method claims, consistent with drug development pathways. In-licensing or licensing negotiations will require careful analysis of the claim language and existing prior art.
Key Takeaways
- U.S. Patent 8,653,260 protects specific chemical compounds and their therapeutic use.
- The scope relies heavily on chemical structure claims with specific substitutions.
- The patent landscape includes multiple filings globally, with a patent expiry around 2033.
- The lack of litigation suggests confidence in enforceability but potential vulnerability to prior art challenges.
- Continuous innovation may be necessary to maintain a competitive edge due to overlapping patents in the therapeutic area.
FAQs
1. How broad are the claims of U.S. Patent 8,653,260?
The claims cover the core chemical structure and specific treatment methods, but they are limited by explicit structural substitutions and therapeutic indications.
2. What patents are related to this patent?
Related patents include prior art involving similar chemical scaffolds and mechanisms, such as US 7,987,646. The patent family also includes filings in Europe and Asia.
3. When does the patent expire?
The patent is expected to expire in 2033, subject to patent term adjustments and maintenance fee payments.
4. Are there any active legal challenges to this patent?
As of 2023, no public reports indicate active litigation or patent disputes.
5. How does this patent fit into the larger patent landscape?
It is part of a cluster of patents protecting similar compounds and therapeutic methods, with intense competition, especially from biotech firms holding related patents.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,653,260.
- Patent landscapes and related filings, European Patent Office (EPO), 2018.
- International Patent Classification (IPC): A61K31/00, C07D 417/12.
- Bloomberg Intelligence. (2022). Biopharma Patent Trends Overview.
- World Intellectual Property Organization (WIPO). Patent landscapes and filings overview, 2022.
More… ↓
⤷ Start Trial
|
